Item 2.02.Results of Operation and Financial Condition.

On May 9, 2022, Precision BioSciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2022. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The Company has updated its corporate deck, which is available in the "Investors & Media" portion of the Company's website at https://investor.precisionbiosciences.com.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.Financial Statements and Exhibits.



  (d) Exhibits




Exhibit
  No.      Description

99.1         Press release of Precision BioSciences, Inc. dated May 9, 2022.
           Cover Page Interactive Data File (embedded within the Inline XBRL document).
104

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses